Glaucoma Clinical Trial
Official title:
Dexmedetomidine as an Additive to Local Anaesthesia to Decrease Intraocular Pressure in Glaucoma Surgery
Nowadays, a number of cases with increased intraocular pressure and glaucoma have been shown
a huge increase . This is because of the increase the geriatric population in the community
and advanced medical care. Surgical correction, as a treatment, solves this problem greatly
especially with the modern surgical techniques .
Peribulbar block reduced the admission discharge time and reduced the burden on both the
patients and the medical team. On the other hand, it carries the risk of increased
intraocular pressure (IOP). Which, subsequently, limit its usage in glaucoma surgery.
Dexmedetomidine, as an alpha 2 agonist, has a well-established role in decreasing
intraocular pressure (IOP). This effect has been shown at a histological level and clinical
level
Nowadays, number of cases with increased intraocular pressure and glaucoma has been shown a
huge increase . This is because of the increase the geriatric population in the community
and advanced medical care. Surgical correction, as a treatment, solves this problem greatly
especially with the modern surgical techniques .
Peribulbar block reduced the admission discharge time and reduced the burden on both the
patients and the medical team. On the other hand, it carries the risk of increased
intraocular pressure (IOP). Which, subsequently, limit its usage in glaucoma surgery .
Dexmedetomidine, as an alpha 2 agonist, has a well established role in decreasing
intraocular pressure (IOP). This effect has been shown at a histological level and clinical
level . It has been tested in many studies before as an additive to local anaesthetic to
augment the effect of the block and to achieve an accepted level of patient sedation (**).
Many routes have been tested such as intravenous infusion, intramuscular injection and
topically with the local anaesthesia . There is a debate about the best route and the
optimum dose that can achieve the desired clinical effect with the least side effects.
There is no study, till now, has examined the effect of Dexmedetomidine in a diseased eye
with pathology that leads to increased IOP. This study states the hypothesis that
Dexmedetomidine locally as an additive to local anaesthesia in different doses, not only
will increase the duration of the block or achieve some level of sedation, but also can
reduce the IOP in this diseased eye to a level that will help the surgical conditions and
improve the surgical outcome.
;
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A |